As of 2025-04-23, the Intrinsic Value of InMed Pharmaceuticals Inc (IN.TO) is -15.73 CAD. This IN.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.19 CAD, the upside of InMed Pharmaceuticals Inc is -475.33%.
Based on its market price of 4.19 CAD and our intrinsic valuation, InMed Pharmaceuticals Inc (IN.TO) is overvalued by 475.33%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.73 - -15.73 | -15.73 | -475.33% |
| P/E | (13.75) - (15.80) | (13.10) | -412.7% |
| DDM - Stable | (12.32) - (52.57) | (32.45) | -874.4% |
| DDM - Multi | (13.50) - (45.66) | (20.94) | -599.9% |
| Market Cap (mil) | 33.73 |
| Beta | 2.27 |
| Outstanding shares (mil) | 8.05 |
| Enterprise Value (mil) | 20.29 |
| Market risk premium | 4.74% |
| Cost of Equity | 8.74% |
| Cost of Debt | 5.00% |
| WACC | 8.68% |